NIKKEI 225
30,500.05+176.75(+0.58%)HANG SENG
23,931.84-988.92(-3.97%)CRUDE OIL
71.32-0.65(-0.90%)GOLD FUTURES
1,748.20-3.20(-0.18%)DOW
34,584.88-166.42(-0.48%)BTC-GBP
33,219.64-1,922.32(-5.47%)
AbbVie Inc. (0QCV.L)
| Previous close | 80.48 |
| Open | 104.39 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 104.39 - 104.39 |
| 52-week range | 104.39 - 104.39 |
| Volume | 400 |
| Avg. volume | N/A |
| Market cap | 133.665B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 24.17 |
| EPS (TTM) | 3.71 |
| Earnings date | 28 Oct 2021 - 01 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Downward Pressures and Flat Earnings Outweigh the AbbVie Inc.'s (NYSE:ABBV) Dividend Yield
AbbVie Inc. (NYSE: ABBV) recently cratered, as modest yearly gains almost got wiped out in a single session. Meanwhile, downward pressure continues as the price looks to test the support around US$100 for the third time this year. We will examine the dividend as the stock dips down below the P/E of 30 since a 4.8% yield is certainly interesting at the right price.
- Business Wire
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
COPENHAGEN, Denmark & NORTH CHICAGO, Ill., September 09, 2021--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is a
- Simply Wall St.
Are Investors Undervaluing AbbVie Inc. (NYSE:ABBV) By 48%?
Does the September share price for AbbVie Inc. ( NYSE:ABBV ) reflect what it's really worth? Today, we will estimate...
